As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Ben Sessa will discuss similarities among MDMA, ketamine, and psilocybin in clinical settings, exploring their potential in treating trauma-based disorders and challenges in psychedelic medicalization.
Ben Sessa
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.
James Keim
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.
Matthew Baggott
"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.
Nirvan Mullick, Dream Mullick
Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.
Norma Stevens
Amanda Feilding, Founder of the Beckley Foundation, drives the Psychedelic Renaissance with groundbreaking research programs at top institutions worldwide, including pioneering studies on psilocybin, LSD, MDMA, and DMT.
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper